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Abbreviations
BCGS Beta cell glucose sensitivity
EGIR European Group for the Study of Insulin Resistance
FPG Fasting plasma glucose
IFG Impaired fasting glucose
IGT Impaired glucose tolerance
NGT Normal glucose tolerance
OGIS Oral glucose insulin sensitivity
1hPG 1 h post-load plasma glucose
2hPG 2 h post-load plasma glucose
RISC Relationship between Insulin Sensitivity and
Cardiovascular Risk
To the Editor: The 1 h post-load plasma glucose (1hPG) mea-
surement has the potential to serve as a sensitive screening
tool for identifying people who, despite having normal glu-
cose tolerance (NGT), are at high-risk of developing type 2
diabetes over the next few years [1, 2]. Screening would be
timely, as beta cells are still functional and lifestyle and drug
interventions may be effective in delaying diabetes onset.
High 1hPG has been found to perform as well as the 2 h
post-load plasma glucose (2hPG) measurement in predicting
type 2 diabetes risk after median follow-up times of 9 and
13 years [3]. In a 33 year study, it was not only a better pre-
dictor of incident diabetes, but also of diabetes complications
and mortality [4]. Robust evidence from the Botnia study and
Malmö Prevention Project cohorts supports 1hPG as the best
simple variable predicting incident type 2 diabetes, in com-
parison with other indices [1].
In a cross-sectional study, we previously described reduced
euglycaemic clamp insulin sensitivity and impaired beta cell
glucose sensitivity (BCGS) in people with NGT but with high
1hPG in 1205 healthy participants in the European Group for
the Study of Insulin Resistance (EGIR) cohort: Relationship
between Insulin Sensitivity and Cardiovascular Risk (RISC)
[2]. There was a significant decreasing trend in insulin sensi-
tivity from NGT with low 1hPG, to NGT with high 1hPG to
impaired glucose tolerance (IGT: 2hPG: 7.8–11.1 mmol/l);
BCGS was significantly higher in those with NGT and low
1hPG, in comparison with NGT and high 1hPG or IGT. This
analysis of NGT included people without IGT and with a
fasting plasma glucose (FPG) <6.1 mmol/l, the WHO defini-
tion of impaired fasting glucose (IFG) [2]. In our previous
cross-sectional analysis of the baseline population, a 1hPG of
8.95 mmol/l was the ‘optimal’ cut-point (maximising [sensi-
tivity + specificity]) associating 1hPG with prevalent IGT [2].
We now report 3 year longitudinal data from 797 partici-
pants with NGT at baseline, who had complete baseline and
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follow-up glucose data (see Table 1). Participants in the RISC
study gave written informed consent. Ethics committee ap-
proval was obtained in each centre. The study was carried
out in accordance with the Declaration of Helsinki as revised
in 2008. The RISC Project Management Board approved the
present analysis. In the present analysis, the definition of NGT
was based on the ADA 2003 criteria (FPG <5.6 mmol/l and
2hPG <7.8 mmol/l, and not being treated for diabetes). The
glucose tolerance status had worsened after 3 years for 183
people (23%): 40 had normal FPG but IGT; 117 had normal
2hPG but IFG (defined as FPG 5.6–6.9 mmol/l); 26 had both
high FPG and 2hPG (including one case of diabetes diagnosed
on the basis of FPG, and one on the basis of 2hPG). There was
a higher percentage of progression to isolated IFG than to
isolated IGT (15% vs 5%), with 3% showing progression on
both FPG and 2hPG.
In the population currently being studied over 3 years of
follow-up, as described in Table 1, the ‘optimal’ cut-point
associated with a worsening glucose status was 7.6 mmol/l,
corresponding to 306 (38%) of our NGT population. After
adjusting for sex, age and BMI, the corresponding cut-point
was 6.2 mmol/l, corresponding to 526 (66%) of our popula-
tion. These frequencies of people at risk of diabetes are prob-
ably too high for these cut-points to be used in practice. A
petition has been published proposing a 1hPG of 8.6 mmol/l
be used as a cut-point for diagnosing IGT, based on a number
of large population based studies [5]; this cut-point identified
177 (22%) in our population.
In the present analysis, the percentage of people whose
glucose status progressed according to 1hPG (electronic sup-
plementary material [ESM] Fig. 1) showed a linear relation—
the higher the 1hPG, the higher the percentage that
progressed—but there is no clear threshold for defining a
cut-point. However, comparing people with a 1hPG
≥8.6 mmol/l with those below this cut-point, the OR of pro-
gression was 2.74 (95% CI 1.90, 3.95); after adjusting the
logistic regression for sex, age and BMI the OR was 2.19
(1.49, 3.20) and this remained statistically significant after
adjusting for either FPG or 2hPG. The 1hPG associated with
progressing according to either FPG or 2hPG, or both, had a C
statistic of 0.67, and this was not significantly different from
those of FPG (0.71) or 2hPG (0.65), using the DeLong test, in
keeping with previous studies [2, 3].
In the current group of 797 participants we present, as
medians (interquartile range) or %, the metabolic features of
individuals with NGT whose glucose status progressed
(‘progressors’) vs those who did not (‘non-progressors’) ac-
cording to 1hPG (< and ≥8.6 mmol/l) at baseline (Table 1).
Comparisons between progressors and non-progressors were
made by logistic regression, unadjusted, and adjusted for sex,
age and BMI. In progressors from both NGT groups, after
adjusting for sex, age and BMI, a higher baseline FPG was
the only common statistically significant risk factor; however
in the low 1hPG group, progressors were older, the 2hPG was
higher and the oral glucose insulin sensitivity (OGIS) index
[6] was lower in progressors than non-progressors; for the
high 1hPG group, basal insulin secretion was higher and the
clamp measure of insulin sensitivity lower in progressors than
in non-progressors, indicating the importance of these two
factors. Over three years of follow-up, the OGIS index de-
creased more in progressors in both 1hPG groups, while in
the low 1hPG group, basal insulin secretion increased more in
progressors (Table 1). The sample sizes in our data are not
large, particularly for the high 1hPG group; we can note that
over three years the BCGS decreasedmore in progressors than
in non-progressors in the high 1hPG group (p = 0.0600).
More people progressed in relation to an increase in FPG
than in 2hPG, 143 (18%) vs 66 (8%) (with 26 of these
progressing in relation to both), so the metabolic features de-
scribed in the paragraph above for progressors reflect more the
metabolic impairment of participants who developed isolated
IFG rather than isolated IGT or combined IFG and IGT; in-
deed we observed a higher clamp insulin sensitivity for isolat-
ed IFG than for isolated IGT, in both 1hPG groups (ESM
Tables 1 and 2). In the low 1hPG group, comparing people
who progressed to isolated IFG or isolated IGT over three
years, basal insulin secretion increased more, total insulin se-
cretion less and OGIS decreased less in those who progressed
to isolated IFG; with the small sample sizes in the high 1hPG
group, no statistically significant differences were seen, but
changes were in the same direction (ESM Tables 1 and 2).
These new data from the RISC study further support the
notion that high 1hPG is associated with an increased risk of
IGT, and also of IFG, and it represents an intermediate risk
category between IFG and IGT, supporting the case to rehabili-
tate the 1hPG test for use in the prediction of type 2 diabetes risk.
The RISC study provides insight on mechanisms involved
in the deterioration of glucose homeostasis in individuals at
risk of type 2 diabetes. The balance between insulin secretion
and insulin sensitivity is central along the progression path-
way to overt diabetes in a continuum of risk. Data from other
cohort studies with similar measures are now required to val-
idate our results.
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EGIR-RISC Investigators
EGIR-RISC recruiting centres
Amsterdam, the Netherlands: RJ Heine, J Dekker, S de
Rooij, G Nijpels, W Boorsma
Athens, Greece: A Mitrakou, S Tournis, K Kyriakopoulou, P
Thomakos
Belgrade, Serbia: N Lalic, K Lalic, A Jotic, L Lukic, M
Civcic
Dublin, Ireland: J Nolan, TP Yeow,MMurphy, C DeLong, G
Neary, MP Colgan, M Hatunic
Frankfurt, Germany: T Konrad, H Böhles, S Fuellert, F
Baer, H Zuchhold
Geneva, Switzerland: A Golay, E Harsch Bobbioni,V
Barthassat, V Makoundou, TNO Lehmann, T Merminod
Glasgow, Scotland, UK: JR Petrie, C Perry, F Neary, C
MacDougall, K Shields, L Malcolm
Kuopio, Finland: M Laakso, U Salmenniemi, A Aura, R
Raisanen, U Ruotsalainen, T Sistonen, M Laitinen, H
Saloranta
London, England, UK: SWCoppack, NMcIntosh, J Ross, L
Pettersson, P Khadobaksh
Lyon, France: M Laville, F Bonnet (now Rennes), A Brac de
la Perriere, C Louche-Pelissier, C Maitrepierre, J Peyrat, S
Beltran, A Serusclat
Madrid, Spain: R Gabriel, EM Sánchez, R Carraro, A Friera,
B Novella
Malmö, Sweden (1): P Nilsson, M Persson, G Östling, (2):O
Melander, P Burri
Milan, Italy: PM Piatti, LD Monti, E Setola, E Galluccio, F
Minicucci, A Colleluori
Newcastle-upon-Tyne, England, UK: M Walker, IM
Ibrahim, M Jayapaul, D Carman, C Ryan, K Short, Y
McGrady, D Richardson
Odense, Denmark: H Beck-Nielsen, P Staehr, K Højlund, V
Vestergaard, C Olsen, L Hansen
Perugia, Italy: GB Bolli, F Porcellati, C Fanelli, P Lucidi, F
Calcinaro, A Saturni
Pisa, Italy: E Ferrannini, A Natali, E Muscelli, S Pinnola, M
Kozakova, A Casolaro, BD Astiarraga
Rome, Italy:GMingrone, C Guidone, A Favuzzi, P Di Rocco
Vienna,Austria: C Anderwald, M Bischof, M Promintzer, M
Krebs, M Mandl, A Hofer, A Luger, W Waldhäusl, M Roden
Project Management Board: B Balkau (Villejuif,
France), F Bonnet (Rennes, France), SW Coppack (London,
England, UK), JM Dekker (Amsterdam, the Netherlands), E
Ferrannini (Pisa, Italy), AMari (Padova, Italy), A Natali (Pisa,
Italy), J Petrie (Glasgow, Scotland, UK), M Walker
(Newcastle, England, UK)
Core laboratories and reading centres
Lipids: Dublin, Ireland: P Gaffney, J Nolan, G Boran
Hormones: Odense, Denmark: C Olsen, L Hansen, H Beck-
Nielsen
Albumin:creatinine: Amsterdam, the Netherlands: A Kok, J
Dekker
Genetics: Newcastle-upon-Tyne, England, UK: S Patel, M
Walker
Stable isotope laboratory: Pisa, Italy: A Gastaldelli, D
Ciociaro
Ultrasound reading centre: Pisa, Italy: M Kozakova
ECG reading: Villejuif, France: MT Guillanneuf
Actigraph: Villejuif, France: B Balkau, L Mhamdi
DataManagement:Villejuif, France, Padova, and Pisa, Italy:
B Balkau, A Mari, L Mhamdi, L Landucci, S Hills, L Mota
Mathematical modelling and website management:
Padova, Italy: A Mari, G Pacini, C Cavaggion, ATura
Coordinating office: Pisa, Italy: SA Hills, L Landucci, L
Mota
Further information on the EGIR-RISC study and partici-
pating centres can be found on www.egir.org.
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